Lipocine Inc. Files 8-K

Ticker: LPCN · Form: 8-K · Filed: 2025-02-06T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, routine-update

TL;DR

Lipocine filed an 8-K, looks like standard procedure, no major news.

AI Summary

Lipocine Inc. filed an 8-K on February 6, 2025, reporting other events and financial statements. The filing does not contain specific details about new material events, acquisitions, or financial results, but rather serves as a procedural update and filing of exhibits.

Why It Matters

This 8-K filing by Lipocine Inc. indicates a routine update or submission of required documents to the SEC, without disclosing new material information that would immediately impact the company's stock.

Risk Assessment

Risk Level: low — The filing is a routine 8-K submission and does not contain any new material information that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Lipocine Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of February 6, 2025.

Does this filing disclose any new material events or financial results for Lipocine Inc.?

Based on the provided text, this filing does not explicitly disclose any new material events or specific financial results; it appears to be a procedural filing.

What is Lipocine Inc.'s Commission File Number?

Lipocine Inc.'s Commission File Number is 001-36357.

Where are Lipocine Inc.'s principal executive offices located?

Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

When was this 8-K report filed by Lipocine Inc.?

This 8-K report was filed on February 6, 2025.

From the Filing

0001493152-25-005108.txt : 20250206 0001493152-25-005108.hdr.sgml : 20250206 20250206093010 ACCESSION NUMBER: 0001493152-25-005108 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250206 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250206 DATE AS OF CHANGE: 20250206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 25595724 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2025-02-06 2025-02-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): February 6, 2025     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   On February 6, 2025, the Company issued a press release announcing that it had received additional regulatory guidance for LPCN 1154. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description       99.1   Lipocine Announces Receipt of Additional LPCN 1154 Regulatory Guidance      

View on Read The Filing